FUNDAMENTAL AND CLINICAL STUDIES ON TA-058

Abstract

From fundamental and clinical studies on TA-058, a new semisynthetic penicillin, the following results were obtained.
1) Peak minimum inhibitory concentrations of TA-058 against clinical isolates, S. aureus, E. coli, K. pneumoniae, P. mirabilis, P. vulgaris, P. aeruginosa were 1.56-6.25, 3.13, 100, 0.2, > 100, 50μg/ml respectively in the low inoculum size.
But in the high inoculum size, antibacterial activities of TA-058 were decreased.
2) TA-058 was administered to 2 cases with respiratory tract infections at a daily dose of 2-4g.
Good effect was observed in the case with chronic bronchitis but poor effect in the case with infected bronchiectasis. No adverse reaction was recognized.